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The thyroid hormone triiodothyronine (T3) plays a fundamental role in growth
regulation, differentiation, metabolism and cellular movement. These processes are
particularly important considering that deregulation of T3 levels could promote abnormal
responsiveness of mammary epithelial cells, which may lead to the development and
progression of breast cancer (BC). Once cells migrate and invade different tissues,
BC metastasis is the main cause of cancer-related death because it is particularly
difficult to revert this multistep process. Cell migration integrates several steps that
induce changes in cell structure and morphology to promote BC cell invasion.
These sequential steps include actin cytoskeleton remodeling, focal adhesion complex
formation and, finally, the turnover of branched actin filament networks. In this article,
we demonstrate that T3 has the ability to modify the Epithelial-Mesenchymal Transition
process. In addition, we show that T3 induces actin cytoskeleton reorganization,
triggers focal adhesion formation and, as a consequence, promotes actin nucleation
via non-genomic pathway. These events are specifically modulated by T3 via integrin
αvβ3 to FAK/paxillin/cortactin/N-WASP/Arp2/3 complex signaling pathway, increasing
cell adhesion, migration and invasion of T-47D BC cells. We suggest that T3 influences
the progression of tumor metastasis by controlling signaling pathways that converge in
cell motility. This knowledge is crucial for the development of novel therapeutic strategies
for BC treatment.
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INTRODUCTION
Breast cancer (BC) is one of the most common cancer types in women worldwide. Nearly 300.000
new cases of invasive BC are registered every year, and more than 10% of the affected patients die
due to this disease (1). Because metastasis is the main cause of death in BC patients, the study
of molecular mechanisms that drive cells into an invasive phenotype could offer new perspectives
for the development of targeted therapies (2). In order to invade distant tissues, BC cells need to
adhere and migrate from the primary tumor, for which actin cytoskeleton reorganization is crucial.
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Deregulation of the signaling pathways that control actin
dynamics marks the onset of cancer progression and metastasis
process (3).
Metastasis consists of several steps that include migration
of cells away from the primary tumor, their invasion of
different tissues and, finally, the generation of a new tumor
(4). To achieve these steps, carcinoma cells change their
shape, losing their apical-basal polarity to acquire a front-
rear polarity that allows cell migration. This process is called
Epithelial-Mesenchymal Transition (EMT) (5). This transition
involves a downregulation of epithelial proteins expression
(E-cadherin) and an upregulation of mesenchymal proteins
(vimentin), driving modifications in cell morphology through
the reorganization of cytoskeletal architecture (5). Recent
studies have demonstrated that the thyroid hormones triiodo-
L-thyronine (T3) and tetraiodo-L-thyronine (T4) enhance EMT
activity and the metastasis process via integrin αvβ3, reducing E-
cadherin and increasing vimentin expression in ovarian cancer
cells (6), but the action of T3 on EMT in BC cells remains to
be determined.
The thyroid hormones (TH), T3 and T4 regulate cell
development, differentiation, metabolism, membrane transport
and morphology (7). TH also support BC development by acting
as proliferative factors and enhancers of cell migration and
invasion (8). T4 has been involved in the promotion of cell
proliferation through the ER by a MAPK-dependent pathway in
MCF-7 BC cells (9). The effects of TH are generally mediated
by genomic mechanisms via nuclear TH receptors that finally
regulate specific gene expression. However, in the last decade,
several studies have supported the existence of non-genomic
or rapid mechanisms triggered by TH, independent of nuclear
receptors (10). These rapid actions can be mediated by different
plasma membrane-receptors, among them integrin αvβ3 (8).
We have recently shown that T3 binds to the integrin αvβ3
receptor, which is highly expressed in several cancer cell lines
(8, 10, 11), and it regulates actin cytoskeleton proteins such as
Src, FAK, and PI3K, increasing BC cell adhesion and migration
(11). Similarly, Lin et al. (12) demonstrated that T3, but not
T4, increases Src/PI3K phosphorylation through integrin αvβ3 in
human glioma cells. These kinases are over-expressed in different
BC cell lines. They activate proteins that are crucial for actinic
nucleation, the final step to trigger BC cell motility (13).
One of these proteins is paxillin, a scaffold protein with several
key domains for the binding of adhesion molecules and the
recruitment of signaling components for actin nucleation (14).
Actinic nucleation, a fundamental mechanism for the
branching of actin filaments, is responsible for modifying the
cell’s cytoskeletal architecture by generating new filaments from
pre-existing ones at the cell’s leading edge. This crucial step
provides the force necessary to trigger cell movement (15, 16).
The Arp2/3 complex is one of the main modulators of this
process; it is activated by nucleation promoter factors, such as
cortactin and N-WASP. Cortactin is able to bind and activate
the Arp2/3 complex by its N-terminal region (17). On the
other hand, N-WASP belongs to the family of the Wiskott–
Aldrich Syndrome Proteins (WASP) and also regulates actinic
nucleation by activating the Arp2/3 complex synergistically with
cortactin (18). Despite the fact that deregulation of these proteins
promotes BC progression, it remains to be studied whether
T3 could modulate cell adhesion, migration and invasion, via
integrin αvβ3, thus controlling cortactin, N-WASP and Arp2/3
complex activity.
The aim of the present study was therefore to continue
elucidating the molecular signal pathway triggered by T3, via
integrin αvβ3, on cell morphology and motility in BC cells. In
particular, we pretended to deepen our understanding of the
rapid actions of T3 on the generation of dynamic structural
modifications of the cytoskeleton through key proteins involved
in actinic nucleation, representing the starting platform for BC
cell migration, invasion, and metastasis.
MATERIALS AND METHODS
Cell Culture and Treatments
The T-47D human breast carcinoma cell line was obtained from
the American Type Culture Collection. T-47D cells were grown
in RPMI 1640 supplemented with L-glutamine (2mM), 10%
fetal bovine serum (FBS), penicillin and streptomycin under
5% CO2 atmosphere at 37
◦C. Before long treatments, BC cells
were kept 24 h in medium containing steroid-deprived FBS.
Before experiments investigating non-transcriptional effects, BC
were kept in medium containing no FBS for 8 h. T3 was
obtained from Sigma-Aldrich, 4-amino-5-(4-chlorophenyl)-7-
(t-butyl)-pyrazolo-(3,4-d) pyrimidine (PP2, 10µM) was from
Calbiochem (La Jolla, CA); and Tetraidothyroacetic acid (Tetrac,
10µM), FAK inhibitor (FAKi, 1µM), Wiskostatin (10µM) and
CK-666 (4µM) were from Santa Cruz Biotechnology (Santa
Cruz, CA). Whenever an inhibitor was used, the compound
was added 45–60min before starting the active treatments.
PP2, FAKi, Wiskostatin and CK-666 were dissolved in DMSO,
Tetrac was dissolved in acetone, and Triiodothyronine (T3) was
dissolved in RPMI 1640 Medium.
Immunoblottings
Cell lysates were separated by SDS-PAGE in 8–10% gels
and transferred into PVDF membranes. Antibodies used
were: p-FAKY397 (611807), FAK (610088) (BD Transduction
Laboratories, Lexington, KY); p-FAK (Tyr397) (sc-11765-R),
cortactin (H-191), p-cortactin (Tyr466), paxillin (T-16), p-
paxillin (Tyr118), E-cadherin (G-10), vimentin (E-5), actin (C-
11) (Santa Cruz Biotechnology); α-Tubulin (T9026) (Sigma
Aldrich); N-WASP (30D10) (Cell Signaling Technology); p-N-
WASP (Ser484/485) (Chemicon International); p-Arp2 (Thr237)
(Biorbyt). Primary and secondary antibodies were incubated with
the membranes using standard techniques. Immunodetection
was accomplished using enhanced chemiluminescence and
recorded with a quantitative digital imaging system (Chemidoc
XRS with Image Lab, Bio-Rad, USA).
Cell Immunofluorescence
T-47D cells were grown on coverslips. Cells were fixed with
4% paraformaldehyde for 30min and permeabilized with 0.1%
Triton for 5min. Blocking was performed with PBS containing
3% bovine serum albumin for 30min at room temperature.
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Cells were incubated with antibodies against p-paxillinY118;
vimentin (E-5) (Santa Cruz Biotechnology); E-cadherin (24E10)
(Cell Signaling Technology); p-N-WASPS484/485 (Chemicon
International); and p-Arp2T237 (Biorbyt) overnight at 4 ◦C,
followed by incubation with DyLight488/ DyLight594 and/or
fluorescein-conjugated secondary antibody (FITC 1:150; Vector
Laboratories, Burlingame, CA). Cells were then incubated with
Texas Red-phalloidin (Sigma-Aldrich, Saint-Louis, MO) for
30min. After washing, the nuclei were counterstained with or
4’-6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, Saint-
Louis, MO) and mounted with Vectashield mounting medium
(Vector Laboratories, Burlingame, CA). Immunofluorescence
was visualized using a Nikon Eclipse E200 microscope and
recorded with a high-resolution DP70 Olympus digital camera.
Gene Silencing With RNA Interference
Synthetic small interfering RNAs targeting paxillin (siRNA
paxillin) and control siRNAs were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The siRNAs were used at the
final concentration of 50 nM. T-47D BC cells were treated 48 h
after siRNAs transfection. Efficacy of gene silencing was checked
with Western analysis and found to be optimal at 48 h.
Transfection Experiments
Dominant negative constructs for cortactin (cortactin3YF, non-
phosphorylatable mutant of cortactin) was generously provided
by Ph.D John Cooper (Washington University School of
Medicine, USA). The inserts were cloned in pcDNA 2AB Flag-
cortactin 3YF (19). The plasmids (10 µg) were transfected into
T-47D cells using Lipofectamine 2000 (Invitrogen, USA). BC
cells were treated 24–48 h after the transfection. Efficacy of
transfection was checked with Western analysis and found to be
optimal at 36 h.
Cell Migration Assay
Cell migration was assayed with razor scrape assays. Briefly,
a razor blade was pressed through the confluent T-47D BC
cell monolayer into the plastic plate to mark the starting line.
T-47D cells were swept away on one side of that line. Cells
were washed, and 2.0mL of RPMI 1640 containing steroid-
deprived FBS and gelatin (1 mg/mL) were added. Cytosine β-
D-arabinofuranoside hydrochloride (Sigma) (10µM), a selective
inhibitor of DNA synthesis that does not inhibit RNA
synthesis, was used 1 h before the test substance was added
to prevent cell proliferation. Immunofluorescence protocol
was performed as previously described in Immunoflourescence
assay. Only the nuclei were counterstained with or 4’-6-
diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, Saint-Louis,
MO) and mounted with Vectashield mounting medium (Vector
Laboratories, Burlingame, CA). Migration was monitored for
48 h. Cells were digitally imaged and the migration distance was
measured by using Nikon Eclipse E200 microscope and recorded
with a high-resolution DP70 Olympus digital camera.
Cell Adhesion Assays
Five hundred thousand cells per well were seeded into 6-well
plates on coverslips previously coated with 1% sterile gelatin
and exposed to different treatments. The cells were incubated
at 37◦C for 2 h. Non-adherent T-47D cells were then removed
by gently washing with PBS. The attached cells were fixed with
4% formaldehyde and stained with 10% ethanol/crystal violet for
20min. Cells of attached images were captured and counted in
10 randomly chosen fields per well using a Nikon Eclipse E200
microscope coupled to a high-resolution CCD digital camera, as
previously described (20).
Cell Invasion Assay
Cell invasion was assayed using the BD BioCoatTM Growth
Factor Reduced (GFR) MatrigelTM Invasion Chamber (BD
Bioscience, USA). In brief, after rehydrating the GFR Matrigel
inserts, the test substance was added to the wells. An equal
number of Control Inserts (no GFR Matrigel coating) were
prepared as control. 0.5mL of T-47D cell suspension (2.5 × 104
cells/mL) was added to the inside of the inserts. Cytosine β-
D-arabinofuranoside hydrochloride (Sigma) (10µM), a selective
inhibitor of DNA synthesis that does not inhibit RNA synthesis,
was used 1 h before the test substance was added to prevent
cell proliferation. The chambers were incubated for 48 h at
37◦C, 5% CO2 atmosphere. After incubation, the non-invading
cells were removed from the upper surface of the membrane
using cotton-tipped swabs. The cells on the lower surface of the
membrane were then stained with Diff-Quick stain. The invading
cells were observed and photographed under the microscope at
100 X magnification. Cells were counted in the central field of
triplicate membranes.
Statistical Analysis
All values are expressed as (mean ± SD) of three independent
experiments. Statistical analysis of the data was performed using
one-way analysis of variance (ANOVA) followed by Barlett’s
multiple comparisons test using GraphPad Prism 5 software. P
< 0.05 was considered as statistically significant.
RESULTS
T3 Enhances EMT in Breast Cancer Cells
Epithelial cells have an inherent plasticity that allows them
to partially or fully transition into mesenchymal cells by
downregulating epithelial and upregulating mesenchymal
characteristics in response to an external signal (5). As TH are
able to rapidly induce EMT in ovarian cancer cell lines (6), as
a first approach we decided to investigate the action of T3 on
E-cadherin and vimentin expression, two important markers of
epithelial and mesenchymal cells, respectively. After treatment
with T3 (10 nM) during different periods (30min, 1, 6, 12, and
24 h), we observed that T3 induced a progressive decrease in
E-cadherin levels starting at 30min, which became statistically
significant at 1 and 6 h and then returned to basal levels at
12 and 24 h (Figures 1A,B). We observed an opposite pattern
when we analyzed the action of T3 on vimentin expression.
T3 increased vimentin levels starting at 30min, which became
significant at 1 and 6 h and returned to basal levels at 12 and
24 h (Figures 1A,B).
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In parallel, we examined the cellular localization of E-cadherin
and vimentin with immunofluorescence analysis after 1 h of T3
treatment. In control cells, we observed that E-cadherin was
intensely localized in the plasma membrane, whereas vimentin
showed a weak cytosplasmatic stain (Figure 1C). After T3
exposure for 1 h, E-cadherin reduced itsmembrane intensity level
whereas vimentin filaments showed an intense cytoplasmatic
stain (Figure 1C).
To determine whether T3 initiates its signaling pathway via
integrin αvβ3, we treated the BC cells with T3 in the presence of
the integrin αvβ3 receptor antagonist tetraiodothyroacetic acid
(Tetrac). Tetrac impaired the expression and redistribution of
both EMT markers (Figures 1C,D). By western blot analysis we
demonstrated that T3 for 1 h induces E-cadherin downregulation
and vimentin upregulation, and this effect was impared by
Tetrac (Figure 1E), suggesting that T3 promotes EMT activity via
integrin αvβ3 in T-47D BC cell.
Thyroid Hormone T3 Induces Rapid
Cytoskeletal and Cell Membrane
Remodeling in BC Cells
To determine the effects of T3 on BC cell morphology,
we analyzed actin cytoskeleton remodeling by means of
an immunofluorescence assay. T3 enhanced actin membrane
reorganization, which was evidenced by a remodeling of the
cytoskeleton toward the plasmatic membrane. The latter led
to a thickening of the membrane and, the formation of
specialized cell membrane structures involved in the generation
of cellular locomotive force, such as lamellipodia, filopodia, and
membrane ruffles (Figure 2A, 20min, red arrows). This event
was time-dependent; a maximal remodeling was observed after
20min of T3 exposure, which returned to basal levels after
60min (Figure 2A).
Cortactin and N-WASP are two important actin nucleation
regulators that are modulated by specific phosphorylation. We
evaluated the phosphorylation of cortactin and N-WASP after
increasing doses of T3 for 20min. We observed that the
phosphorylation of both proteins was maximal with 10 nM
(Figures 2B,C) and therefore used this concentration for the rest
of the experiments.
In addition, T3 rapidly induced Ser484/485 N-WASP
phosphorylation in a time-dependent manner, with a
maximal effect at 20min and a return to basal levels after
60min (Figures 2D,E).
T3 Signal to FAK/paxillin Phosphorylation
via Integrin αvβ3 Increasing T-47D
Cell Migration
We evaluated the role of diverse protein kinases in the cascades
involved in the signaling to cortactin and N-WASP in BC
FIGURE 1 | T3 modulates EMT via E-cadherin and vimentin expression. (A) T-47D BC cells were treated with T3 for different times (30min, 1, 6, 12, and 24 h) and
Western blot expression patterns for E-cadherin and vimentin were performed. (B) E-cadherin and vimentin densitometry values were adjusted to actin intensity, then
normalized to the control sample. Results are expressed as mean ± S.D. *P < 0.05 vs. control. (C,D) An immunofluorescence assay and Western blot analysis were
performed to determine E-cadherin and vimentin expression and localization in BC cells. Cells were treated with T3 for 1 h, in the presence or absence of Tetrac. Cells
were stained with E-cadherin linked to DyLight594 and vimentin linked to DyLight488; nuclei were counterstained with DAPI. CON, Control. (E) Each EMT marker
densitometry values were adjusted to actin intensity, then normalized to the control sample. Results are expressed as the mean ± S.D. *P < 0.05 vs. control. #P <
0.05 vs. control. The experiments were performed in triplicate; representative images are shown.
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FIGURE 2 | T3 induces dynamic actin remodeling in BC cells. (A) T-47D cells
were treated for different times with T3 (10 nM). Actin fibers were stained with
phalloidin linked to Texas Red (red labeling) and nuclei were counterstained
with DAPI (blue labeling). The inserts show the generation of dynamic
structural modifications of the cytoskeleton, with the development of
protrusive membrane structures, such as lamellipodia and filopodia at higher
magnification. (B,C) Dose-dependent and (D,E) time-dependent cortactin and
N-WASP phosphorylation of T-47D cells after T3 treatment. Total cell amount
of wild-type cortactin and phosphorylated cortactin (p-cortactinY466 ) or
N-WASP and phosphorylated N-WASP (p-N-WASPS484/5) are shown by
Western blot analysis. Phospho-cortactin and p-N-WASP densitometry values
were adjusted to cortactin and N-WASP intensity, respectively, then
normalized to the control sample. *P < 0.05 vs. corresponding control. All
experiments were performed in triplicate with consistent results; representative
images are shown.
cells. We had previously determined that T3 induces rapid
phosphorylation of Src, FAK and PI3K, via integrin αvβ3, and
promotes BC cell motility (11). We thus analyzed two central
proteins involved in focal adhesion complex formation, FAK
and paxillin phosphorylation/activation, after T3 stimulation
in T-47D cells. We observed that a rapid pulse of 10 nM T3
(20min) increased FAKTyr397 and paxillinTyr118 phosphorylation
and that this effect was prevented by the integrin αvβ3 receptor
antagonist Tetrac (Figures 3A,B). Src and FAK are the main
kinases involved in focal adhesion signaling; they are responsible
for the recruitment and phosphorylation of paxillin.We therefore
used pharmacological inhibitors of Src (PP2) and FAK (FAKi) in
cells exposed to T3 and observed that the increase of phospho-
FAKTyr397 and phospho-paxillinTyr118 was impaired by PP2 and
FAKi, suggesting that T3 induces paxillin phosphorylation via Src
and FAK (Figures 3C,D).
To determine the role of paxillin in the formation of focal
adhesion complex, we next examined its subcellular localization
in the presence of T3 by means of immunofluorescence. Breast
cancer cells treated with T3 triggered a significant increase of
phospho-paxillinTyr118 at the cell membrane periphery where
cortical actin complexes were formed, and this was impaired
by the blockade of Src (PP2), FAK (FAKi), and paxillin
(siRNAs) (Figures 3E,F).
Finally, we evaluated BC cell migration through a wound-
healing assay during exposure to T3 during 48 h. We observed
that T3 significantly enhanced BC cell migration; this effect was
prevented by the use of PP2, FAKi and the silencing of paxillin
with specific siRNAs (Figures 3G,H). Altogether, these results
suggest that T3 signals to paxillin through a Src/FAK cascade.
When paxillin is phosphorylated, it consequently translocates to
the cell periphery, promoting BC cell migration.
Intracellular Events Linking Activation of
Paxillin to Cortactin, N-WASP and
Arp2/3 Complex
In order to continue elucidating the signaling by which T3
enhances BC cell movement, we evaluated the role of paxillin
toward three fundamental components of actin nucleation:
cortactin, N-WASP and Arp2/3 complex. We observed that the
rapid treatment with 10 nM of T3 (20min) significantly increased
the phosphorylation levels of paxillin, cortactin, N-WASP and
the subunit Arp2 (Arp2/3 complex) (Figures 4A,B). Paxillin
phosphorylation was only prevented by the use of the specific
siRNA vs. paxillin, whereas phospho-cortactin was inhibited by
the siRNA vs. paxillin and its dominant-negative cortactin3YF
construct (cortactin3YF), but not with the specific inhibitor of N-
WASP,Wiskostatin. Finally, N-WASP andArp2 phosphorylation
were markedly reduced by the silencing of paxillin, blockade
of cortactin3YF and the inhibition of N-WASP (Figures 4A,B),
suggesting that integrin αvβ3 signals to Arp2/3 complex via FAK,
paxillin, cortactin, and N-WASP.
The efficacy of transfections was assayed by Western blot.
The siRNA of paxillin significantly reduced its expression
(Figures 4C,D), whereas the expression of cortactin3YF construct
significantly increased the amount of cortactin present in these
BC cells (Figures 4E,F).
We next evaluated the subcellular localization of
phosphorylated N-WASPS484/485 and Arp2T237/238. In control
cells, phospho-N-WASP and phospho-Arp2 were weakly
distributed throughout the cytoplasm (Figures 4G,H). T3
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FIGURE 3 | T3 promotes FAK and paxillin phosphorylation through integrin αvβ3. (A) T-47D cells were treated with T3 (10 nM) for 20min in the presence or absence
of Tetrac. Total cell amount of wild-type FAK and paxillin, or phospho-FAK and p-paxillin, are shown with Western blot. (B) Phospho-FAK and phospho-paxillin
densitometry values were adjusted to FAK and paxillin intensity, respectively, then normalized to the control sample. Results are expressed as the mean ± S.D. *P <
0.05 vs. control. #P < 0.05 vs. control. (C) Cells were exposed to T3 (10 nM) for 20min in the presence or absence of PP2 (10µM) and FAK (1µM), and FAK and
paxillin phosphorylation were analyzed through Western blot assay. (D) Phospho-FAK and p-paxillin densitometry values were adjusted to FAK and paxillin and/or
actin intensity and normalized to the control. Results are expressed as the mean ± S.D. *P < 0.05 vs. control. #P < 0.05 vs. control. (E) BC cells were stained with
anti-phospho-paxillinTyr118 linked to FITC, filamentous actin was stained with phalloidin linked to Texas Red and nuclei were counterstained with DAPI. CON, Control.
Yellow arrows indicate membrane-localized paxillinTyr118-. (F) Quantification of the membrane-localized p-paxillin in the different conditions. Results are expressed as
Dots/cells (mean ± SD). *P < 0.05 vs. control. Membrane-localized p-paxillin was counted in 40 different cells. The experiments were repeated three times with
consistent results. (G) Cells were treated with T3 (10 nM) for 48 h in the presence or absence of PP2, FAKi and siRNA paxillin. Representative images are shown.
Migration assay was monitored at 48 h by taking photographs. DAPI was used to stain nucleus and Gap closure was quantified with the use of NIH image J software.
*P < 0.05 vs. control. (H) Cell migration distances were measured; values are presented as % of control. *P < 0.05 vs. control. The experiments were performed in
triplicate with consistent results; representative images are shown.
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FIGURE 4 | T3 signals to paxillin, cortactin, N-WASP and Arp2/3 complex. (A,B) T-47D cells were incubated in the presence of 10 nM T3 for 20min with or without
silencing of paxillin with specific siRNAs and/or inhibition of cortactin and N-WASP. Actin, phospho-paxillinY118, p-cortactinY466, p-N-WASPS484/485 and p-Arp2Y237
were assayed in cell extracts. The densitometry values were adjusted to actin intensity, then normalized to the control sample. (C–F) T-47D cells were transfected,
with paxillin-targeted siRNAs or the dominant negative constructs of cortactin (cortactin3YF) and incubated with T3 (10 nM) for 20min. Paxillin protein expression was
detected by Western blot, and actin intensity was used as loading control. Paxillin and cortactin densitometry values were adjusted to actin intensity, then normalized
to the control sample. *P < 0.05 vs. corresponding control. (G) Cells were stained with anti-phospho-N-WASPS484/485 linked to FITC (green) and (H)
phospho-Arp2T237/8 linked to FITC (green), filamentous actin was stained with phalloidin linked to Texas Red and nuclei were counterstained with DAPI. CON,
Control. Yellow arrows indicate membrane-localized p-N-WASPS484/485 and p-Arp2T237/8. All experiments were performed in triplicate with consistent results;
representative images are shown.
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FIGURE 5 | BC cell adhesion and invasion is triggered by T3 via paxillin/cortactin-N-WASP/ Arp 2/3 Complex pathway. T-47D cells were treated with T3 (10 nM) for
2 h (A) and 48 h (C) in the presence or absence of Wiskostatin or CK-666, and transfected with siRNAs vs. paxillin or mutant constructs for cortactin (cortactin3YF ).
(A) After the treatment, cells were placed on coverslips previously covered with gelatin and a cell adhesion assay was performed. Representative images of adhered
cells are shown. (B) Percentage of attached cells vs. CON, Control cells. Experiments were performed in triplicate; *P < 0.05 vs. CON. (C) Breast cancer cell invasion
through matrigel was assayed with invasion chambers. Representative images in chambers with matrigel are shown. (D) Invading cells were counted in the central
field of triplicate membranes. *P < 0.05 vs. CON.
exposure for 20min increased N-WASPS484/485 and Arp2T237/238
phosphorylation and translocation to the plasmatic membrane
(Figures 4G,H). This relocalization was prevented by the use of
cortactin3YF (Figure 4G) and Wiskostatin (Figure 4H).
T3 Enhances Cell Adhesion and Invasion
via Paxillin/Cortactin/N-WASP/Arp2/3
Complex
We performed an adhesion and three-dimensional invasion
assay using Matrigel to determine the ability of cancer cells
to adhere and invade the surrounding environment. Treatment
with T3 (10 nM) enhanced the capacity of BC cells to adhere
(Figures 5A,B, yellow arrows) and invade ECM (Figures 5C,D,
yellow arrows). This ability was drastically diminished in
treatments where specific inhibitors were used, such as siRNA
paxillin, cortactin3YF, Wiskostatin and the specific inhibitor of
the Arp2/3 complex (CK-666) (Figures 5A,D). These results
support the concept that paxillin, cortactin, N-WASP and Arp2/3
Complex are involved in adhesion and cellular invasion processes
triggered by T3.
DISCUSSION
In the last years, several studies have evidenced a link between
thyroid hormones (TH) and cancer development (21).
Because TH regulate growth, differentiation, development
and metabolism, altered levels of these hormones could
play a significant role in the development and progression
of diverse types of cancer, including breast cancer (BC).
Published works about the relationship between hyper- and
hypothyroidism and the incidence of BC are controversial.
Some authors consider hypothyroidism an important enhancer
factor in invasion and metastasis (22), other studies suggest
that hypothyroidism does not affect, or, rather, reduces the
risk of developing the disease (23), whereas other not found
association between hypothyroidism or hyperthyroidism
and BC (24). In addition, an important association between
hyperthyroidism and the risk of developing BC has been
established (25, 26). Søgaard et al. (27) described an
increased risk of BC in women with hyperthyroidism and
a slightly reduced risk in women with hypothyroidism,
suggesting that a correlation exists between TH levels and
BC risk.
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FIGURE 6 | Schematic signaling cascade triggered by T3 promoting BC cell
migration and invasion. Binding of T3 to the specific membrane integrin αvβ3
receptor induces phosphorylation of the Src/FAK/paxillin/cortactin/N-WASP/
Arp2/3 Complex cascade, promoting BC cell motility.
Furthermore, a significant positive associations between
higher prediagnostic T3 levels, larger tumors and occurrence of
lymph node metastases have been demonstrated, suggesting that
this association, can be related to both a higher incidence and
more aggressive forms of BC, increasing BC mortality (28).
For this reason, in this work we evaluated the effect of T3 in
a supraphysiological concentration (10 nM) taking into account
that altered levels of this hormone could be related with BC.
We have previously shown that reducing T3 levels
downregulates the expression of key cell motility regulators,
such as Src, FAK, and PI3K kinase, in T-47D BC cells (11).
In the present work we observed that treatment with T3
(10 nM) results in a maximal phosphorylation of cortactin and
N-WASP (Figures 2B,C), which suggests that altered levels of
T3 affect BC cells’ ability to induce the adhesion, migration and
invasion processes.
As a first approach, we studied the involvement of T3 in
the epithelial-mesenchymal transition (EMT), a key step for
the early development of metastasis. We observed a progressive
reduction of E-cadherin expression and an increase in vimentin
expression in a time-dependent manner, being maximal at 1 h
and returning to basal levels at 12 and 24 h. We also showed, by
means of immunofluorescence experiments, that these changes
were accompanied by a reduction of E-cadherin at the plasma
membrane and an increase in the intensity of vimentin filaments
in the cytoplasm. Lamouille et al. (5) have described that
during the EMT initiation, E-cadherin expression is reduced
because it is cleaved at the plasma membrane and degraded in
the cytoplasm. This could explain the protein level reduction
observed in this work. Furthermore, an increased expression
of intermediate filaments, such as vimentin, is necessary to
determine the beginning of the transition (29), by promoting
the directional cell migration by regulating microtubule polarity
and focal adhesion dynamics (30). Previous works have also
reported this altered expression of E-cadherin/vimentin in
response to TH. Weingarten et al. (6) have determined that 1-
4 h of T3 and T4 treatment drastically increases the expression
of vimentin and reduces E-cadherin mRNA level to half of
its basal level in OVCAR-3 and SKOV-3 ovarian cancer cell
lines. They demonstrated that the modifications in EMT proteins
were mediated by integrin αvβ3 membrane receptor, which is
consistent with our results (6). The EMT is an orchestrated
sequential steps process in which cell-cell and cell-extracellular
matrix (ECM) interactions are modified to release epithelial
cells from the surrounding tissue, along with actin cytoskeleton
rearrangements to confer cells the ability to migrate through
a three-dimensional ECM. In fact, TH are capable of modify
the expression of several and crucial components of ECM. In
mouse mammary epithelial cells, T3 increases the expression
of the proteases stromelysin 1 and 2 and stimulates their
activity leading to a gelatinolytic activity of type IV collagenase
(31). In human hepatoma cells and fibroblast, T3 induces
fibronectin expression by activating hypoxia-inducible factor-1
(HIF-1) (32). Furthermore, in astrocytes TH regulates integrin
interactions with ECM proteins like laminin, being essential for
their migration during brain development (33, 34). These studies
indicate that TH may exert an integrated regulation of tumor
progression by modifying the ECM, the EMT and the signaling
pathways implicated in cell migration and invasion. Our study,
specifically reveals that T3 enhance the EMT and this leads to
an important cell cytoskeleton reorganization, increasing cellular
motility and enabling cells to develop an invasive phenotype
driven by T3.
Another finding of this work is that T3 stimulates
morphological changes that depend on the generation of
dynamic structural modifications of the actin cytoskeleton
reorganization, via actin polymerization/depolymerization,
in association with specialized membrane structures, such as
lamellipodia, filopodia and membrane ruffles. These structures
are fundamental to promote cell adhesion, migration and
invasion processes.
Cell adhesion is carried out by different integrins including
αvβ3 that recruits Src and FAK kinases, which are critical for
the formation of focal adhesion (FAs) complexes (16, 34, 35).
Cohen et al. (36) have shown that T3 and T4 regulate adhesion,
migration and matrix metalloproteinase activity via integrin
αv/β3 in myeloma cells. We have previously reported that T3,
via integrin αvβ3, represents the starting platform to activate
Src, FAK, and PI3K, which leads to increased BC cell motility
(11). We have not evaluated the use of Tetrac to block cell
adhesion, migration and invasion, but Weingarten et al. (6)
are currently developing a nano-particle antagonist of thyroid-
integrin binding that could represent a novel agent that may
limit the metastasic potential of cancer cells. For this reason,
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we continued evaluating the non-genomic effects of T3 on
several kinases and scaffold proteins related to cell movement,
such as paxillin. Paxillin has many binding partners and acts
as a pivot molecule between the formation of focal adhesion
complex and the actin nucleation, key steps in the regulation of
cell motility (3, 37). Our results show that T3 induces paxillin
phosphorylation whereas the specific integrin αvβ3 receptor
antagonist Tetrac inhibits this action. Once paxillin is activated
by T3, it translocates to sites where FAs are formed. This effect
is dependent on integrin αvβ3, Src and FAK proteins. This
finding is in agreement with our previous work, in which we
have shown that paxillin is recruited to FAs by Src and FAK
in response to rapid treatments of BC cells with estradiol (37).
Similarly, Deramaudt et al. (38) have shown that a FAK mutant
construct deficient in binding paxillin disrupts FA formation
and drastically reduces cell adhesion, migration and invasion of
mouse fibroblasts.When paxillin is phosphorylated and recruited
to FAs, it becomes a docking site for many downstream signaling
molecules, among them the actin nucleation regulators cortactin
and N-WASP (37, 39).
Actin nucleation is crucial for directional cell motility
through the actin polymerization process. The latter involves
the generation and turnover of actin filaments, which form
subcellular structures (lamellipodia and filopodia) that are key
for cell movement. In this context, many signaling pathways
drive actin nucleation by regulating actin-binding protein
activity. In order to be functional, Arp2/3 complex needs to
be activated by proteins called nucleation promoting factors
or NPFs. In this work we evaluated the role of T3 on
two main NPFs, cortactin and N-WASP. We identified the
recruitment of the FAK/paxillin/cortactin by T3, which is a step
required for N-WASP and Arp2/3 complex phosphorylation and
translocation to the plasma membrane. Blocking this event by
using specific inhibitors or mutant constructs drastically affects
cell adhesion and invasion, which highlights the importance of
actin nucleation proteins in tumor progression. These findings
emphasize the relevance of the cortactin/N-WASP/Arp2/3
complex phosphorylation and regulation for cancer metastasis.
The discovery that cortactin/N-WASP controls the Arp2/3
complex via thyroid hormones may thus offer novel insights to
better understand the action of these hormones on BCmetastasis,
although there is considerable evidence of the role of TH in
enhancing metastasis in several types of cancer (40). The use of
specific NPF inhibitors could thus be an attractive alternative
to counteract the ability of BC cells to metastasize. Although
no drug is available to target cortactin, Dasatinib is currently
used to disrupt the Src/cortactin signaling pathway for blocking
BC metastasis (41). A recent study demonstrated that using
nanobodies to target the VCA domain of N-WASP results in a
diminished invasiveness of breast, prostate, and head and neck
squamous cancer cells by disrupting N-WASP/Arp2/3 complex
interaction (42).
Additionally, we also studied the phosphorylation of Arp2
subunit, which is fundamental to the fully functioning of
Arp2/3 complex (43). Our results suggest that paxillin,
cortactin, and N-WASP relay signals from integrin αvβ3 to the
Arp2/3 complex.
One limitation of this study is the use of only one BC cell line.
Also, it would be interesting to validate these findings in other
models, mainly in primary cell cultures because integrin αv/β3 is
universally expressed in cancer cells.
In conclusion, our findings provide new insights about
the non-genomic action of T3 in BC cell progression via
integrin αvβ3/FAK/paxillin/cortactin/N-WASP/Arp2/3 complex
(Figure 6). We observed how T3 induces rapid alterations in
the plasma membrane, leading to a rearrangement of the actin
cytoskeleton and consequent formation of structures related with
cell motility, increasing cell adhesion, migration, and invasion in
T-47D BC cells. These findings could be helpful to develop new
drugs that interfere with the ability of breast tumors to diffuse
locally or at distant sites in patients with thyroid disorders and
breast cancer, counteracting BC cell progression by controlling
circulating T3 levels.
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